Express News | InMode Announces Morpheus8 FDA 510(k) Clearance For Soft Tissue Contraction For Fractional Radiofrequency Microneedling
Express News | Morpheus8 Secures First and Only FDA Clearance for Soft Tissue Contraction for Fractional Radiofrequency Microneedling
Barclays Lowers Price Target on InMode to $29 From $33, Maintains Overweight Rating
InMode (INMD) has an average outperform rating and price target range of $16 to $29, according to analysts polled by Capital IQ.Price: 17.78, Change: -0.10, Percent Change: -0.53
InMode Price Target Cut to $29.00/Share From $33.00 by Barclays
InMode Price Target Cut to $29.00/Share From $33.00 by
InMode Is Maintained at Overweight by Barclays
InMode Is Maintained at Overweight by
Express News | Inmode : Barclays Cuts Target Price to $29 From $33
Barclays Maintains InMode(INMD.US) With Buy Rating, Maintains Target Price $29
Barclays analyst Matt Miksic maintains $InMode(INMD.US)$ with a buy rating, and maintains the target price at $29.According to TipRanks data, the analyst has a success rate of 60.4% and a total
Barclays Maintains InMode(INMD.US) With Buy Rating, Cuts Target Price to $29
Barclays analyst Matt Miksic maintains $InMode(INMD.US)$ with a buy rating, and adjusts the target price from $33 to $29.According to TipRanks data, the analyst has a success rate of 61.1% and a
InMode Price Target Cut to $16.00/Share From $21.00 by Canaccord Genuity
InMode Price Target Cut to $16.00/Share From $21.00 by Canaccord
InMode Is Maintained at Hold by Canaccord Genuity
InMode Is Maintained at Hold by Canaccord
Canaccord Genuity Adjusts InMode's PT to $16 From $21, Keeps Hold Rating
10:19 AM EDT, 07/12/2024 (MT Newswires) -- Canaccord Genuity Adjusts InMode's PT to $16 From $21, Keeps Hold RatingPrice: 17.74, Change: +0.92, Percent Change: +5.47
Express News | Canaccord Genuity Maintains Hold on InMode, Lowers Price Target to $16
Jefferies Maintains InMode(INMD.US) With Buy Rating, Cuts Target Price to $21
Jefferies analyst Matthew Taylor maintains $InMode(INMD.US)$ with a buy rating, and adjusts the target price from $31 to $21.According to TipRanks data, the analyst has a success rate of 60.5% and a
Express News | Inmode Ltd : Jefferies Cuts Target Price to $21 From $24
Express News | InMode Sees Q2 Revenue Between $86.2M-$86.3M, Pro-Forma Revenue Between $102.4M-$102.5M Vs $116.58M Est, Decreases FY 2024 Guidance To $430M-$440M Vs $479.5M Est
Express News | Inmode Ltd - Expects Q2 Revenue Between $86.2M-$86.3M
Express News | Inmode Ltd Sees Full Year 2024 Revenue to Be $430 Mln to $440 Mln
Express News | Inmode to Report Second Quarter 2024 Financial Results and Hold Conference Call on Aug. 1, 2024
InMode (NASDAQ:INMD): An Opportunity for a Potential Upward Revision
InMode Ltd. (NASDAQ:INMD) Is Favoured by Institutional Owners Who Hold 67% of the Company
To get a sense of who is truly in control of InMode Ltd. (NASDAQ:INMD), it is important to understand the ownership structure of the business. The group holding the most number of shares in the company, around 67% to be precise, is institutions. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).